Status:
TERMINATED
Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hypercholesterolemia
Mixed Dyslipidemia
Eligibility:
All Genders
18+ years
Brief Summary
This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean...
Eligibility Criteria
Inclusion
- Participants who are treated with TREDAPTIVE tablet within current local label for the first time
- Participants with primary hypercholesterolemia or mixed dyslipidemia
- Participants who are treated with TREDAPTIVE for more than or equal to 24 weeks will be included in long-term surveillance
- Special participants with known hepatic disorder or renal disorder, participants 65 years old or older, participants younger than 19 years old, and pregnant woman will be evaluated if collected.
Exclusion
- Participant who is treated with TREDAPTIVE tablet before contract and out of enrollment period
- Participant who has a contraindication to TREDAPTIVE tablet according to the current local label
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
1166 Patients enrolled
Trial Details
Trial ID
NCT01228019
Start Date
December 1 2010
End Date
May 1 2013
Last Update
April 21 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.